Indication
Malignant neoplasm of liver
A malignant neoplasm of the liver is a cancerous tumor originating within hepatic tissue, most commonly presenting in adult populations as hepatocellular carcinoma or intrahepatic cholangiocarcinoma. Read more about Malignant neoplasm of liver
4 drugs 4 manufacturers
Drugs that treat it
Common Malignant neoplasm of liver therapies.
FLOXURIDINE
FLOXURIDINE
FLOXURIDINE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonA malignant neoplasm of the liver is a cancerous tumor originating within hepatic tissue, most commonly presenting in adult populations as hepatocellular carcinoma or intrahepatic cholangiocarcinoma.
Pathophysiologically, these malignancies typically arise in the setting of chronic hepatic inflammation, injury, and cirrhosis driven by risk factors such as chronic hepatitis B or C infection, alcohol-related liver disease, or metabolic dysfunction-associated steatotic liver disease.
Malignant transformation leads to uncontrolled cellular proliferation, architectural disruption of hepatic parenchyma, and potential vascular invasion into the portal or hepatic venous systems.
Clinical manifestations often emerge at advanced stages and include right upper quadrant abdominal pain, hepatomegaly, unexplained weight loss, ascites, and worsening hepatic decompensation or jaundice.
- cancer.gov
A malignant neoplasm of the liver is a cancerous tumor originating within hepatic tissue, most commonly presenting in adult populations as hepatocellular carcinoma or intrahepatic cholangiocarcinoma Clinical manifestations often emerge at advanced stages and include right upper quadrant abdominal pain, hepatomegaly, unexplained weight loss, ascites, and worsening hepatic decompensation or jaundice
- mayoclinic.org
A malignant neoplasm of the liver is a cancerous tumor originating within hepatic tissue, most commonly presenting in adult populations as hepatocellular carcinoma or intrahepatic cholangiocarcinoma Malignant transformation leads to uncontrolled cellular proliferation, architectural disruption of hepatic parenchyma, and potential vascular invasion into the portal or hepatic venous systems
- nih.gov
Pathophysiologically, these malignancies typically arise in the setting of chronic hepatic inflammation, injury, and cirrhosis driven by risk factors such as chronic hepatitis B or C infection, alcohol-related liver disease, or metabolic dysfunction-associated steatotic liver disease
- wikipedia.org
Pathophysiologically, these malignancies typically arise in the setting of chronic hepatic inflammation, injury, and cirrhosis driven by risk factors such as chronic hepatitis B or C infection, alcohol-related liver disease, or metabolic dysfunction-associated steatotic liver disease Clinical manifestations often emerge at advanced stages and include right upper quadrant abdominal pain, hepatomegaly, unexplained weight loss, ascites, and worsening hepatic decompensation or jaundice
- bund.de
Malignant transformation leads to uncontrolled cellular proliferation, architectural disruption of hepatic parenchyma, and potential vascular invasion into the portal or hepatic venous systems
Personalize your experience
Follow Malignant neoplasm of liver and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.